Phenotypes Associated with This Genotype

Genotype
MGI:3839882

• Allelic Composition: Kmt2a^tm1.1Erns/Kmt2a^tm1.1Erns; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S2/SvPas * C57BL/6 * CBA * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:147265 )

• mice die within days of pIpC treatment unlike similarly treated wild-type mice

• however, pIpC-treated mice injected with wild-type bone marrow survive

hematopoietic system

abnormal definitive hematopoiesis ( J:147265 )

• myelo-erythroid progenitor cells from pIpC-treated mice exhibit reduced proliferation and a 2.6-fold reduction in re-entry into the cell cycle following serum and cytokine starvation compared to wild-type cells

• however, the composition of cell populations produced is normal

decreased common myeloid progenitor cell number ( J:147265 )

• 11 days after pIpC, treatment common myeloid progenitors, granulocyte-progenitors, and megakaryocyte-erythrocyte progenitors are decreased 1.4- to 4-fold compared to in wild-type mice

• cultured bone marrow cells of pIpC-treated mice exhibit a 2- to 5-fold decrease in myeloid colonies compared to wild-type cells

decreased bone marrow cell number ( J:147265 )

• pIpC-treated mice exhibit bone marrow cytopenia unlike in wild-type mice

abnormal common lymphocyte progenitor cell morphology ( J:147265 )

• 11 days after pIpC treatment, lymphocyte progenitor cells are decreased 1.4- to 4-fold compared to in wild-type mice

• cultured bone marrow cells of pIpC-treated mice exhibit a 2- to 5-fold decrease in lymphoid colonies compared to wild-type cells

decreased erythroid progenitor cell number ( J:147265 )

• 11 days after pIpC, treatment common myeloid progenitors, granulocyte-progenitors, and megakaryocyte-erythrocyte progenitors are decreased 1.4- to 4-fold compared to in wild-type mice

• cultured bone marrow cells of pIpC-treated mice exhibit a 2- to 5-fold decrease in erythroid colonies compared to wild-type cells

abnormal hematopoietic stem cell morphology ( J:147265 )

• pIpC-treated mice exhibit a loss of hematopoietic stem cell (HSC) renewal followed by an increase in HSC proliferation and subsequent depletion of these cells unlike in wild-type mice

decreased hematopoietic stem cell number ( J:147265 )

• pIpC-treated mice exhibit a cell-intrinsic loss of hematopoietic stem cell-enriched KSL populations and loss of hematopoietic stem cell activity unlike similarly treated wild-type mice